What is the effect of fezolinetant on patient-reported outcomes?

Published

In the Phase 3 trials SKYLIGHT 1 and 2 (pooled data) and DAYLIGHT, fezolinetant demonstrated improvements over placebo in Menopause-Specific Quality of Life (MENQoL) Total and Domain scores, and Patient Global Impression of Change in vasomotor symptoms (PGI-C VMS)

  • Health-related quality of life (HRQoL) assessments were exploratory endpoints of these studies during the double-blind periods.1,2 

find-my-msl

Find My MSL

Medical Science Liaisons are available to help answer your scientific questions.

submit

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

adverse

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)